Melasema. Chloasma
Conditions
Interventions
Intervention 1: Administration of the 250 mg Transxamic Acid Capsule Amin Pharmaceutical Company, Trancid capsule 250 milligram, is administered every 12 hours.On patients with melasma at the age of 1
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients with melasma with 18- 60 years old rang.
Exclusion criteria
Exclusion criteria: Patients with coagulopathy Patients with thrombotic complications Any of thrombotic events Use of anticoagulant drugs or anti-platelet such as aspirin or Clopidogrel Pregnancy, lactation, concomitant use of contraceptives, The history of vitiligo or other pigmentation disorders, Trancexamic Acid Sensitivity History renal failure History of treatment for melasma with clarifying drugs in 3 months before the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pigmentation. Timepoint: MASIS record before intervention - one month and three months after intervention. Method of measurement: MASI Score. | — |
Secondary
| Measure | Time frame |
|---|---|
| Gastrointestinal complications. Timepoint: before intervention - one month and three months after intervention. Method of measurement: Ask the patients.;Hypomenorea. Timepoint: before intervention - one month and three months after intervention. Method of measurement: ASk the patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamin Vala
Ahvaz University of Medical Sciences
Outcome results
None listed